-
August 28, 2017PREVIEW
Use of canagliflozin (Invokana—Janssen) in patients with type 2 diabetes who had established cardiovascular (CV) disease or CV risk factors resulted in a 14% reduction in the composite endpoint of...
-
August 1, 2017PREVIEW
Patients who received aspirin-based antiplatelet treatment after a vascular event and were not on routine proton pump inhibitors (PPIs), particularly those who were 75 years of age or older, were...
-
July 24, 2017PREVIEW
Data from more than 50 randomized controlled trials (RCTs) showed that opioid analgesic–related pharmacokinetic (PK) drug–drug interactions with various agents including antiplatelet agents,...
-
July 24, 2017PREVIEW
Results of a retrospective analysis of patients with atrial fibrillation (AF) initiated on apixaban (Eliquis—Bristol-Myers Squibb), dabigatran (Pradaxa—Boehringer Ingelheim), or rivaroxaban (...
-
July 17, 2017PREVIEW
In patients with hypertension, reductions in systolic blood pressure (SBP) to levels of 120 mm Hg to 124 mm Hg resulted in greater reductions in the risk of major cardiovascular disease (CVD),...
Pages
